Literature DB >> 11761912

[A case of Hirayama's disease successfully treated by anterior cervical decompression and fusion].

H Imamura1, S Matsumoto, M Hayase, Y Oda, H Kikuchi, M Takano.   

Abstract

The authors report the case of a 16-year-old boy with Hirayama's disease(juvenile muscular atrophy of unilateral upper extremity). The present history began about 6 months previously, when he noticed slowly progressive weakness with atrophy of the left hand and forearm. Neurological examination on admission revealed diffuse distribution of muscular atrophy including the left hypothenar, thenar, forearm, and triceps muscles. However, EMG studies identified neurogenic changes in both upper extremities. There was no long tract sign of objective sensory impairment. Plain spinal radiograms showed abnormal kyphosis of the cervical vertebrae. Cervical MR images in the neutral position demonstrated focal atrophy of the cervical cord at the C 5-6 vertebral levels. When the neck was flexed, the cervical cord was displaced anteriorly and was compressed over the posterior surface of the C 5-6 vertebral bodies. He was diagnosed to have Hirayama's disease(cervical flexion myelopathy). Via an anterior approach, he underwent a C 5 vertebrectomy followed by fixation of C 4-6 vertebral bodies using iliac bone and plate system. He recovered from surgery without any complications and has been well for the past 6 months with remarkable improvement of muscle strength. Application of cervical collar for 3 to 4 years has been generally advocated for the treatment of Hirayama's disease because progression of signs and symptoms is usually expected to cease within several years. However, some patients were reported not to response to conservative treatment for more than 5 years after their onsets. To these patients surgery seems to be beneficial, because it can give rise to permanent stable fixation with much shorter period of external cervical immobilization compared with cervical collar therapy, in which long-term application is frequently unbearable in many patients. In conclusion, the present case emphasizes the importance of surgical treatment in Hirayama's disease not only to improve neurological deficits but regain better quality of life.

Entities:  

Mesh:

Year:  2001        PMID: 11761912

Source DB:  PubMed          Journal:  No To Shinkei        ISSN: 0006-8969


  6 in total

1.  Hirayama's disease: an Italian single center experience and review of the literature.

Authors:  Valerio Vitale; Ferdinando Caranci; Chiara Pisciotta; Fiore Manganelli; Francesco Briganti; Lucio Santoro; Arturo Brunetti
Journal:  Quant Imaging Med Surg       Date:  2016-08

2.  Vietnamese Case Series of Hirayama Disease.

Authors:  Nguyen Duy Hung; Nguyen Minh Duc; Nguyen Thanh VAN; LE Thanh Dung; Hoang Duc Ha; Nguyen Duy Hue
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 3.  Nosology of juvenile muscular atrophy of distal upper extremity: from monomelic amyotrophy to Hirayama disease--Indian perspective.

Authors:  Kaukab Maqbool Hassan; Hirdesh Sahni
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

4.  Magnetic resonance imaging features of "Proximal" hirayama disease: Case report and literature review.

Authors:  Ramakrishna Narra; Suseel Kumar Kamaraju
Journal:  Surg Neurol Int       Date:  2021-12-20

5.  How to reconstruct the lordosis of cervical spine in patients with Hirayama disease? A finite element analysis of biomechanical changes focusing on adjacent segments after anterior cervical discectomy and fusion.

Authors:  Xiao Lu; Fei Zou; Feizhou Lu; Xiaosheng Ma; Xinlei Xia; Jianyuan Jiang
Journal:  J Orthop Surg Res       Date:  2022-02-16       Impact factor: 2.359

6.  Can preoperative cervical spinal diffusion tensor imaging (DTI) indices predict surgical outcomes in patients with Hirayama disease? A retrospective cohort study.

Authors:  Yuan Gao; Chi Sun; Shuyi Zhou; Xiaosheng Ma; Xinlei Xia; Feizhou Lu; Jun Zhang; Hongli Wang; Jianyuan Jiang
Journal:  Front Neurol       Date:  2022-09-30       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.